Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

BEAMBeam Therapeutics Inc.

Nasdaq · CIK 0001745999
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts272

Identity from submissions API

NameBeam Therapeutics Inc.
CIK0001745999
TickersBEAM
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2836 Biological Products, (No Diagnostic Substances)
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone857-327-8775
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • Beam Therapeutics Inc. (2018-08-09T00:00:00.000Z → 2026-11-13T00:00:00.000Z)
Business address
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
MA
Mailing address
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

515 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-126822 005-91369 261550635 34 13679
2026-11-03 10-Q 10-Q 0001193125-26-444455 001-39208 261514509 34 12811111 1 1
2026-11-03 8-K 8-K 2.02,9.01 0001193125-26-444454 001-39208 261514497 34 439153 1 1
2026-10-16 4 4 0001193125-26-424421 15097
2026-10-16 144 xsl144X01/primary_doc.xml 0001950047-26-010282 001-39208 261466199 33 5495
2026-10-15 144 xsl144X01/primary_doc.xml 0001950047-26-010253 001-39208 261463330 33 4807
2026-10-02 4 4 0001193125-26-412236 5066
2026-09-25 4 4 0001193125-26-402814 5720
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-096939 005-91369 261280196 34 13534
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000908834-26-000397 005-91369 261274876 34 49379
2026-08-04 10-Q 10-Q 0001193125-26-331541 001-39208 261235433 34 12347478 1 1
2026-08-04 8-K 8-K 2.02,9.01 0001193125-26-331522 001-39208 261235423 34 416906 1 1
2026-07-29 4 4 0001193125-26-323640 5264
2026-07-27 144 xsl144X01/primary_doc.xml 0001950047-26-007314 001-39208 261205713 33 5993
2026-07-02 4 4 0001193125-26-294478 5056
2026-07-01 4 4 0001193125-26-292526 22777
2026-06-30 144 xsl144X01/primary_doc.xml 0001950047-26-006639 001-39208 261140753 33 6871
2026-06-29 144 xsl144X01/primary_doc.xml 0001950047-26-006578 001-39208 261135907 33 6871
2026-06-29 4 4 0001193125-26-288078 10155
2026-06-22 4 4 0001193125-26-277509 10231
2026-06-08 8-K 8-K 5.07 0001193125-26-261693 001-39208 261072585 34 202824 1 1
2026-06-05 4 4 0001193125-26-259529 5417
2026-06-05 4 4 0001193125-26-259526 5456
2026-06-05 4 4 0001193125-26-259524 5410
2026-06-05 4 4 0001193125-26-259536 5452
2026-06-05 4 4 0001193125-26-259534 5437
2026-06-05 4 4 0001193125-26-259519 5463
2026-05-07 10-Q 10-Q 0001193125-26-210338 001-39208 26950862 34 13205192 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-210299 001-39208 26950815 34 358756 1 1
2026-04-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-000189 005-91369 26917513 34 7323
2026-04-17 ARS ARS 0001193125-26-161561 001-39208 26871721 34 1550703
2026-04-17 DEFA14A DEFA14A 0001193125-26-161541 001-39208 26871622 34 1332390
2026-04-17 DEF 14A DEF 14A 0001193125-26-161512 001-39208 26871517 34 4623957 1 1
2026-04-14 144 xsl144X01/primary_doc.xml 0001950047-26-003430 001-39208 26861127 33 4648
2026-04-06 4 4 0001193125-26-144086 6049
2026-04-06 4 4 0001193125-26-144080 5382
2026-04-06 4 4 0001193125-26-144068 5121
2026-04-06 4 4 0001193125-26-144067 5091
2026-04-06 4 4 0001193125-26-144054 5105
2026-04-02 4 4 0001193125-26-140586 5059
2026-04-02 4 4 0001193125-26-140553 5087
2026-04-02 4 4 0001193125-26-140515 5068
2026-04-02 4 4 0001193125-26-140513 5058
2026-04-02 4 4 0001193125-26-140508 5072
2026-04-01 4 4 0001193125-26-138348 17074
2026-03-31 144 xsl144X01/primary_doc.xml 0001193125-26-134721 001-39208 26822610 33 6238
2026-03-31 144 xsl144X01/primary_doc.xml 0001193125-26-134691 001-39208 26822421 33 5037
2026-03-31 144 xsl144X01/primary_doc.xml 0001193125-26-134661 001-39208 26822270 33 4394
2026-03-31 144 xsl144X01/primary_doc.xml 0001193125-26-134643 001-39208 26822199 33 5676
2026-03-31 144 xsl144X01/primary_doc.xml 0001950047-26-003089 001-39208 26822130 33 6870
2026-03-30 144 xsl144X01/primary_doc.xml 0001950047-26-003060 001-39208 26812940 33 6182
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-000785 005-91369 26798347 34 7088
2026-03-05 8-K 8-K 1.02 0001193125-26-093914 001-39208 26726088 34 145878 1 1
2026-02-26 4 4 0001193125-26-076544 8770
2026-02-24 144 xsl144X01/primary_doc.xml 0001950047-26-001698 001-39208 26671797 33 4748
2026-02-24 S-8 S-8 0001193125-26-065214 333-293671 26667516 33 371389 1 1
2026-02-24 10-K 10-K 0001193125-26-065194 001-39208 26667451 34 18624514 1 1
2026-02-24 8-K 8-K 1.01,2.02,2.03,9.01 0001193125-26-065191 001-39208 26667437 34 464451 1 1
2026-02-12 8-K 8-K 1.01,9.01 0001193125-26-048684 001-39208 26626127 34 230197 1 1
2026-02-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-26-000023 005-91369 26609491 34 7932
2026-02-05 8-K 8-K 5.02 0001193125-26-039365 001-39208 26602870 34 140433 1 1
2026-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000908834-26-000048 005-91369 26602484 34 65230
2026-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-26-000356 005-91369 26601811 34 11496
2026-02-03 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-009583 005-91369 26590922 34 12740
2026-02-02 4 4 0001193125-26-033605 5324
2026-02-02 4 4 0001193125-26-033606 5290
2026-02-02 4 4 0001193125-26-033603 5294
2026-02-02 4 4 0001193125-26-033601 5295
2026-02-02 4 4 0001193125-26-033600 24501
2026-02-02 4 4 0001193125-26-033598 5303
2026-01-30 144 xsl144X01/primary_doc.xml 0001950047-26-000761 001-39208 26583315 33 5494
2026-01-29 144 xsl144X01/primary_doc.xml 0001950047-26-000741 001-39208 26577834 33 4806
2026-01-26 4 4 0001193125-26-022563 5135
2026-01-26 4 4 0001193125-26-022557 4611
2026-01-22 144 xsl144X01/primary_doc.xml 0001950047-26-000626 001-39208 26551564 33 7296
2026-01-21 4 4 0001193125-26-017942 4622
2026-01-20 4 4 0001193125-26-016552 8886
2026-01-15 144 xsl144X01/primary_doc.xml 0001950047-26-000494 001-39208 26537216 33 8371
2026-01-12 8-K 8-K 2.02,7.01,9.01 0001193125-26-009722 001-39208 26524617 34 12030432 1 1
2026-01-05 4 4 0001193125-26-002448 4918
2026-01-05 4 4 0001193125-26-002427 4917
2026-01-05 4 4 0001193125-26-002422 4930
2025-12-11 8-K 8-K 2.01 0001193125-25-316043 001-39208 251565404 34 145368 1 1
2025-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002693 005-91369 251452570 34 11498
2025-11-04 10-Q 10-Q 0001193125-25-263542 001-39208 251446429 34 12105028 1 1
2025-11-04 8-K 8-K 2.02,9.01 0001193125-25-263536 001-39208 251446414 34 415652 1 1
2025-10-29 4 4 0001193125-25-255853 7760
2025-10-08 4 4 0001193125-25-234461 7920
2025-10-03 4 4 0001193125-25-230195 4952
2025-10-03 4 4 0001193125-25-230148 4899
2025-10-03 4 4 0001193125-25-230084 15350
2025-10-02 144 xsl144X01/primary_doc.xml 0001950047-25-007703 001-39208 251369490 33 5495
2025-10-01 144 xsl144X01/primary_doc.xml 0001950047-25-007616 001-39208 251364769 33 4807
2025-08-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-075081 005-91369 251192515 34 13663
2025-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001955 005-91369 251188260 34 11112
2025-08-05 10-Q 10-Q 0000950170-25-102393 001-39208 251182780 34 11513126 1 1
2025-08-05 8-K 8-K 2.02,9.01 0000950170-25-102389 001-39208 251182762 34 420854 1 1
2025-08-01 4 4 0000950170-25-101143 7765
2025-07-03 4 4 0000950170-25-094002 6719
2025-07-03 8-K 8-K 3.02 0000950170-25-093906 001-39208 251105923 34 142501 1 1
2025-06-06 4 4 0000950170-25-083056 5319
2025-06-06 4 4 0000950170-25-083055 5315
2025-06-06 4 4 0000950170-25-083054 5280
2025-06-06 4 4 0000950170-25-083051 5334
2025-06-06 4 4 0000950170-25-083053 5273
2025-06-06 4 4 0000950170-25-083050 5325
2025-06-06 4 4 0000950170-25-083052 5300
2025-06-06 8-K 8-K 5.07 0000950170-25-083043 001-39208 251030528 34 187898 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001072613-25-000405 005-91369 25955183 34 33493
2025-05-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000908834-25-000171 005-91369 25939637 34 47657
2025-05-06 10-Q 10-Q 0000950170-25-063966 001-39208 25915243 34 10507319 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-063955 001-39208 25915194 34 356726 1 1
2025-04-18 ARS ARS 0000950170-25-055863 001-39208 25850514 34 2103215
2025-04-18 DEFA14A DEFA14A 0000950170-25-055857 001-39208 25850472 34 1322953
2025-04-18 DEF 14A DEF 14A 0000950170-25-055853 001-39208 25850427 34 6094419 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000564 005-91369 25844557 34 10994
2025-04-10 3 3 0000950170-25-052693 6975
2025-04-03 4 4 0000950170-25-050859 5442
2025-04-03 4 4 0000950170-25-050857 6386
2025-04-03 4 4 0000950170-25-050856 5461
2025-04-03 4 4 0000950170-25-050855 5478
2025-04-03 4 4 0000950170-25-050852 7501
2025-04-02 4 4 0000950170-25-049769 4922
2025-04-02 4 4 0000950170-25-049765 4927
2025-04-02 4 4 0000950170-25-049763 4935
2025-04-02 4 4 0000950170-25-049761 4950
2025-04-02 4 4 0000950170-25-049759 5635
2025-04-02 144 xsl144X01/primary_doc.xml 0001950047-25-002326 001-39208 25804477 33 5406
2025-04-02 4/A 4/A 0000950170-25-049297 8638
2025-04-02 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001019 005-91369 25802716 34 11359
2025-03-31 144 xsl144X01/primary_doc.xml 0000950170-25-047961 001-39208 25795851 33 4396
2025-03-31 144 xsl144X01/primary_doc.xml 0000950170-25-047960 001-39208 25795849 33 5669
2025-03-31 144 xsl144X01/primary_doc.xml 0000950170-25-047959 001-39208 25795847 33 5632
2025-03-31 144 xsl144X01/primary_doc.xml 0000950170-25-047958 001-39208 25795845 33 4424
2025-03-10 424B5 424B5 0001193125-25-051106 333-277427 25724941 33 714608 1 1
2025-03-10 8-K 8-K 1.01,8.01,9.01 0001193125-25-051072 001-39208 25724654 34 654550 1 1
2025-03-10 FWP FWP 0001193125-25-050346 333-277427 25722038 34 74680
2025-03-10 424B5 424B5 0001193125-25-050343 333-277427 25722029 33 533672
2025-03-10 8-K 8-K 7.01,8.01,9.01 0001193125-25-050334 001-39208 25722011 34 202637 1 1
2025-02-25 S-8 S-8 0000950170-25-026086 333-285182 25659458 33 714804 1 1
2025-02-25 10-K 10-K 0000950170-25-026076 001-39208 25659408 34 19479546 1 1
2025-02-25 8-K 8-K 2.02,9.01 0000950170-25-026070 001-39208 25659395 34 426443 1 1
2025-02-20 4 4 0000950170-25-024149 4626
2025-02-19 4 4 0000950170-25-023166 11922
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001072613-25-000167 005-91369 25630379 34 35389
2025-02-14 144 xsl144X01/primary_doc.xml 0001950047-25-000859 001-39208 25628457 33 5435
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000727 005-91369 25612332 34 11370
2025-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000908834-25-000047 005-91369 25594983 34 56910
2025-02-03 4 4 0000950170-25-012307 5284
2025-02-03 4 4 0000950170-25-012306 5315
2025-02-03 4 4 0000950170-25-012305 5307
2025-02-03 4 4 0000950170-25-012304 9530
2025-02-03 4 4 0000950170-25-012303 5313
2025-01-30 144 xsl144X01/primary_doc.xml 0001950047-25-000495 001-39208 25573876 33 4812
2025-01-13 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-25-004558 001-39208 25524766 34 17833239 1 1
2025-01-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-002732 005-91369 25524552 34 7044
2025-01-06 4 4 0000950170-25-002358 5397
2025-01-06 4 4 0000950170-25-002355 5418
2025-01-02 4 4 0000950170-25-000624 7238
2024-12-30 144 xsl144X01/primary_doc.xml 0000950170-24-141235 001-39208 241590890 33 5056
2024-12-30 144 xsl144X01/primary_doc.xml 0000950170-24-141233 001-39208 241590884 33 5050
2024-12-19 4 4 0000950170-24-138447 6724
2024-12-19 3 3 0000950170-24-138427 16666
2024-12-09 8-K 8-K 7.01,8.01,9.01 0001193125-24-272860 001-39208 241533830 34 231738 1 1
2024-12-06 8-K 8-K 5.02,7.01,9.01 0001193125-24-271965 001-39208 241530527 34 174301 1 1
2024-12-04 4 4 0000950170-24-133080 5305
2024-12-04 3 3 0000950170-24-133078 16122
2024-12-04 8-K 8-K 5.02,7.01,9.01 0001193125-24-270314 001-39208 241524796 34 163026 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002690 005-91369 241444467 34 7907
2024-11-08 4 4 0000950170-24-124085 5086
2024-11-08 SC 13G/A us07373v1052_110824.txt 0002012383-24-003439 005-91369 241439525 34 13971
2024-11-07 SC 13G/A beam_13ga.htm 0000908834-24-000290 005-91369 241433632 34 482130
2024-11-05 10-Q 10-Q 0000950170-24-121104 001-39208 241425936 34 9805544 1 1
2024-11-05 8-K 8-K 8.01,9.01 0000950170-24-121099 001-39208 241425911 34 216457 1 1
2024-11-05 8-K 8-K 7.01,9.01 0000950170-24-121088 001-39208 241425872 34 15792283 1 1
2024-11-05 8-K 8-K 2.02,9.01 0000950170-24-121069 001-39208 241425595 34 334869 1 1
2024-10-21 SC 13G/A us07373v1052_102124.txt 0002012383-24-000930 005-91369 241383529 34 13959
2024-10-17 SC 13G/A Beam_Therapeutics_Inc.htm 0000093751-24-000811 005-91369 241376580 34 55963
2024-10-16 4 4 0000950170-24-115031 15885
2024-10-15 144 xsl144X01/primary_doc.xml 0001968582-24-000929 001-39208 241370691 33 7382
2024-10-07 144 xsl144X01/primary_doc.xml 0001972362-24-001399 001-39208 241358433 33 4207
2024-10-02 4 4 0000950170-24-111739 5400
2024-10-02 4 4 0000950170-24-111737 7301
2024-10-02 4 4 0000950170-24-111732 6053
2024-09-30 144 xsl144X01/primary_doc.xml 0001950047-24-007469 001-39208 241340116 33 4819
2024-09-03 4 4 0000950170-24-102823 5329
2024-08-19 3 3 0000950170-24-098531 24846
2024-08-06 10-Q 10-Q 0000950170-24-091242 001-39208 241177270 34 9705060 1 1
2024-08-06 8-K 8-K 2.02,9.01 0000950170-24-091201 001-39208 241177056 34 331595 1 1
2024-07-15 8-K 8-K 5.02,9.01 0001193125-24-178824 001-39208 241115850 34 167317 1 1
2024-07-03 4 4 0000950170-24-081492 6775
2024-06-28 4 4 0000950170-24-079065 5828
2024-06-27 144 xsl144X01/primary_doc.xml 0001950047-24-005051 001-39208 241079434 33 6196
2024-06-10 8-K 8-K 5.07 0000950170-24-071345 001-39208 241033163 34 172413 1 1
2024-06-07 4 4 0000950170-24-070793 5287
2024-06-07 4 4 0000950170-24-070790 5279
2024-06-07 4 4 0000950170-24-070788 5399
2024-06-07 4 4 0000950170-24-070783 5332
2024-06-07 4 4 0000950170-24-070768 5325
2024-06-07 4 4 0000950170-24-070766 5321
2024-05-07 10-Q 10-Q 0000950170-24-053939 001-39208 24919601 34 8756614 1 1
2024-05-07 8-K 8-K 2.02,9.01 0000950170-24-053928 001-39208 24919577 34 277510 1 1
2024-04-29 4 4 0000950170-24-049854 7273
2024-04-19 ARS ARS 0000950170-24-046028 001-39208 24858097 34 2315334
2024-04-19 DEFA14A DEFA14A 0000950170-24-046022 001-39208 24858033 34 1292823
2024-04-19 DEF 14A DEF 14A 0000950170-24-046017 001-39208 24857936 34 4615381 1 1
2024-04-04 144 xsl144X01/primary_doc.xml 0000950170-24-042028 001-39208 24824526 33 5678
2024-04-04 144 xsl144X01/primary_doc.xml 0000950170-24-042027 001-39208 24824525 33 4424
2024-04-04 144 xsl144X01/primary_doc.xml 0000950170-24-042026 001-39208 24824522 33 4430
2024-04-04 144 xsl144X01/primary_doc.xml 0000950170-24-042025 001-39208 24824520 33 5030
2024-04-04 144 xsl144X01/primary_doc.xml 0000950170-24-042024 001-39208 24824517 33 5004
2024-04-03 4 4 0000950170-24-041441 7486
2024-04-03 4 4 0000950170-24-041438 5437
2024-04-03 4 4 0000950170-24-041437 5459
2024-04-03 4 4 0000950170-24-041432 11127
2024-04-03 4 4 0000950170-24-041426 10423
2024-04-02 144 xsl144X01/primary_doc.xml 0001950047-24-002884 001-39208 24814579 33 5413
2024-04-02 4 4 0000950170-24-040154 5227
2024-04-02 4 4 0000950170-24-040152 5210
2024-04-02 4 4 0000950170-24-040151 4945
2024-04-02 4 4 0000950170-24-040150 4932
2024-04-01 4 4 0000950170-24-039319 7940
2024-03-28 144 xsl144X01/primary_doc.xml 0001950047-24-002764 001-39208 24801045 33 5507
2024-02-28 S-3ASR S-3ASR 0001193125-24-048201 333-277427 24689032 33 1559103
2024-02-27 S-8 S-8 0000950170-24-020628 333-277382 24682013 33 320287
2024-02-27 10-K 10-K 0000950170-24-020622 001-39208 24681972 34 17475784 1 1
2024-02-27 8-K 8-K 2.02,9.01 0000950170-24-020608 001-39208 24681861 34 343816 1 1
2024-02-15 4 FORM 4 SUBMISSION 0001209191-24-003394 12474
2024-02-14 SC 13G/A ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS -- SCH 13G/A(#2) 0001072613-24-000251 005-91369 24636714 34 277435
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020412 005-91369 24627643 34 13032
2024-02-12 SC 13G/A beam_13ga.htm 0000908834-24-000051 005-91369 24619589 34 433172
2024-02-09 SC 13G/A filing.txt 0000315066-24-000973 005-91369 24611349 34 7910
2024-02-06 SC 13G/A SC 13G/A 0001193125-24-024797 005-91369 24598086 34 42983
2024-02-02 4 4 0000950170-24-010480 5329
2024-02-02 4 4 0000950170-24-010479 5305
2024-02-02 4 4 0000950170-24-010478 5312
2024-02-02 4 4 0000950170-24-010477 8372
2024-02-02 4 4 0000950170-24-010474 5319
2024-01-31 144 xsl144X01/primary_doc.xml 0001950047-24-000541 001-39208 24583561 33 4819
2024-01-29 SC 13G/A SC 13G/A 0001104659-24-007680 005-91369 24573531 34 52877
2024-01-25 SC 13G/A us07373v1052_012524.txt 0001086364-24-003822 005-91369 24563025 34 13610
2024-01-24 SC 13G Beam_Therap_Inc.txt 0000093751-24-000121 005-91369 24554364 34 8479
2024-01-08 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-24-002673 001-39208 24518250 34 12875704 1 1
2024-01-05 4 4 0000950170-24-002480 4905
2023-12-27 4 FORM 4 SUBMISSION 0001209191-23-059756 7450
2023-12-14 4 4 0000950170-23-070395 5207
2023-12-14 3 3 0000950170-23-070390 14637
2023-12-14 8-K 8-K 5.02,9.01 0001193125-23-295457 001-39208 231487117 34 162194 1 1
2023-11-22 4 4 0000950170-23-065868 13242
2023-11-20 144 xsl144X01/primary_doc.xml 0001950047-23-005224 001-39208 231423032 33 5353
2023-11-08 10-Q 10-Q 0000950170-23-060683 001-39208 231385959 34 11237987 1 1
2023-11-08 8-K 8-K 2.02,9.01 0000950170-23-060660 001-39208 231385897 34 419017 1 1
2023-11-01 4 4 0000950170-23-057499 4512
2023-10-31 8-K 8-K 2.01,3.02,8.01,9.01 0000950170-23-056542 001-39208 231362217 34 206266 1 1
2023-10-30 144 xsl144X01/primary_doc.xml 0001950047-23-004631 001-39208 231360895 33 5233
2023-10-24 4 4 0000950170-23-054850 6654
2023-10-19 8-K 8-K 2.05,7.01,8.01,9.01 0001193125-23-258963 001-39208 231333446 34 3452880 1 1
2023-10-12 UPLOAD filename1.pdf 0000000000-23-011145 39661
2023-10-04 4 4 0000950170-23-051915 4823
2023-09-22 SC 13G beam13g.htm 0000908834-23-000114 005-91369 231271451 34 608928
2023-09-20 CORRESP filename1.htm 0001193125-23-238645 114368
2023-08-22 UPLOAD filename1.pdf 0000000000-23-009179 48244
2023-08-09 CORRESP filename1.htm 0001193125-23-207411 61303
2023-08-09 4 4 0000950170-23-040574 4838
2023-08-08 10-Q 10-Q 0000950170-23-039364 001-39208 231149341 34 11892459 1 1
2023-08-08 8-K 8-K 2.02,9.01 0000950170-23-039356 001-39208 231149285 34 427707 1 1
2023-07-25 4 4 0000950170-23-034518 17755
2023-07-21 144 xsl144X01/primary_doc.xml 0001968582-23-000350 001-39208 231103456 33 5973
2023-07-20 UPLOAD filename1.pdf 0000000000-23-007716 45113
2023-06-08 4 4 0000950170-23-027060 9017
2023-06-08 4 4 0000950170-23-027049 5229
2023-06-08 4 4 0000950170-23-027046 5222
2023-06-08 4 4 0000950170-23-027045 5218
2023-06-08 4 4 0000950170-23-027040 5237
2023-06-08 4 4 0000950170-23-027037 5178
2023-06-08 8-K 8-K 5.07 0000950170-23-027026 001-39208 231002363 34 213962 1 1
2023-05-10 424B5 424B5 0001193125-23-140856 333-254946 23907612 33 343900
2023-05-10 8-K 8-K 1.01,9.01 0001193125-23-140832 001-39208 23907416 34 200850 1 1
2023-05-10 10-Q 10-Q 0000950170-23-020090 001-39208 23904349 34 10944013 1 1
2023-05-10 8-K 8-K 2.02,9.01 0000950170-23-020063 001-39208 23904275 34 363838 1 1
2023-04-21 ARS ARS 0000950170-23-013848 001-39208 23836542 34 1361068
2023-04-21 DEFA14A DEFA14A 0000950170-23-013842 001-39208 23836477 34 1325429
2023-04-21 DEF 14A DEF 14A 0000950170-23-013837 001-39208 23836394 34 4787592 1 1
2023-04-19 4/A 4/A 0000950170-23-013483 5725
2023-04-05 4 FORM 4 SUBMISSION 0000899243-23-010819 7790
2023-04-05 4 FORM 4 SUBMISSION 0000899243-23-010818 6853
2023-04-05 4 FORM 4 SUBMISSION 0000899243-23-010817 6826
2023-04-05 4 FORM 4 SUBMISSION 0000899243-23-010816 9122
2023-04-05 4 FORM 4 SUBMISSION 0000899243-23-010815 7090
2023-03-31 4 FORM 4 SUBMISSION 0000899243-23-010140 12962
2023-03-31 4 FORM 4 SUBMISSION 0000899243-23-010138 7582
2023-03-31 4 FORM 4 SUBMISSION 0000899243-23-010137 14139
2023-03-31 4 FORM 4 SUBMISSION 0000899243-23-010134 5090
2023-03-31 4 FORM 4 SUBMISSION 0000899243-23-010132 7576
2023-03-27 3 FORM 3 SUBMISSION 0000899243-23-009751 13171
2023-03-27 3 FORM 3 SUBMISSION 0000899243-23-009750 17641
2023-03-17 SC 13G SC 13G 0001193125-23-073117 005-91369 23740611 34 43198
2023-02-28 S-8 S-8 0000950170-23-004870 333-270079 23678444 33 270161
2023-02-28 10-K 10-K 0000950170-23-004866 001-39208 23678381 34 23066884 1 1
2023-02-28 8-K 8-K 2.02,9.01 0000950170-23-004858 001-39208 23678309 34 449540 1 1
2023-02-14 SC 13G/A 13ga1_beam.htm 0001175707-23-000059 005-91369 23622837 34 628462
2023-02-10 SC 13G/A SC 13G/A 0001104659-23-018201 005-91369 23609624 34 40557
2023-02-10 SC 13G/A SC 13G/A 0001193125-23-031112 005-91369 23608457 34 79815
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015434 005-91369 23602539 34 12951
2023-02-09 SC 13G/A filing.txt 0000315066-23-001344 005-91369 23601201 34 7769
2023-02-02 SC 13G/A us07373v1052_020223.txt 0001306550-23-006547 005-91369 23580869 34 13402
2023-01-30 4 FORM 4 SUBMISSION 0000899243-23-002957 15235
2023-01-25 4 FORM 4 SUBMISSION 0000899243-23-002666 15234
2023-01-20 4 FORM 4 SUBMISSION 0000899243-23-002260 9684
2023-01-09 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-23-004131 001-39208 23516534 34 13643690 1 1
2023-01-05 4 FORM 4 SUBMISSION 0000899243-23-000973 22518
2023-01-03 4 FORM 4 SUBMISSION 0000899243-23-000237 7546
2022-12-20 4/A FORM 4/A SUBMISSION 0000899243-22-039103 6146
2022-12-14 4 FORM 4 SUBMISSION 0000899243-22-038538 17297
2022-11-07 10-Q 10-Q 0000950170-22-022322 001-39208 221363732 34 14010047 1 1
2022-11-07 8-K 8-K 2.02,9.01 0000950170-22-022313 001-39208 221363672 34 476260 1 1
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034759 18411
2022-09-08 4 PRIMARY DOCUMENT 0000315066-22-001715 11276
2022-09-07 8-K 8-K 8.01 0000950170-22-018147 001-39208 221229878 34 167903 1 1
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030277 5321
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030278 5354
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030271 5289
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030272 5347
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030269 5340
2022-09-02 4 FORM 4 SUBMISSION 0000899243-22-030270 5335
2022-08-30 8-K 8-K 8.01 0000950170-22-017868 001-39208 221212881 34 165250 1 1
2022-08-09 10-Q 10-Q 0000950170-22-015755 001-39208 221146415 34 12755222 1 1
2022-08-09 8-K 8-K 2.02,9.01 0000950170-22-015736 001-39208 221146319 34 417257 1 1
2022-08-08 4 PRIMARY DOCUMENT 0000315066-22-001678 20030
2022-08-01 8-K 8-K 8.01,9.01 0000950170-22-013559 001-39208 221122697 34 201954 1 1
2022-07-29 4 FORM 4 SUBMISSION 0000899243-22-027077 19973
2022-07-14 SC 13G INITIAL 13G 0000908834-22-000110 005-91369 221083028 34 430804
2022-06-10 8-K 8-K 5.07 0000950170-22-011501 001-39208 221009653 34 234847 1 1
2022-05-09 10-Q 10-Q 0000950170-22-008238 001-39208 22903255 34 11449891 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008231 001-39208 22903201 34 353479 1 1
2022-05-02 4 FORM 4 SUBMISSION 0000899243-22-016164 30035
2022-04-22 DEFA14A DEFA14A 0000950170-22-006017 001-39208 22845937 34 300932
2022-04-22 DEF 14A DEF 14A 0000950170-22-006016 001-39208 22845891 34 1670824
2022-04-14 4 PRIMARY DOCUMENT 0000315066-22-001561 24065
2022-04-04 4 FORM 4 SUBMISSION 0000899243-22-013489 6852
2022-04-04 4 FORM 4 SUBMISSION 0000899243-22-013487 7722
2022-04-04 4 FORM 4 SUBMISSION 0000899243-22-013485 7005
2022-02-28 S-8 S-8 0001193125-22-055894 333-263067 22684055 33 85639
2022-02-28 10-K 10-K 0000950170-22-002166 001-39208 22683923 34 19130584 1 1
2022-02-28 8-K 8-K 2.02,9.01 0000950170-22-002162 001-39208 22683873 34 409957 1 1
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-023120 005-91369 22634475 34 74720
2022-02-14 SC 13G/A BEAM THERAPEUTICS INC. 0000902664-22-001711 005-91369 22631310 34 55674
2022-02-14 SC 13G/A ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS -- SCH 13G/A(#1) 0001072613-22-000149 005-91369 22627831 34 270690
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-039200 005-91369 22624945 34 98016
2022-02-09 SC 13G SCHEDULE 13G 0001104659-22-016611 005-91369 22606539 34 12916
2022-02-09 SC 13G/A SC 13G/A 0001104659-22-016108 005-91369 22605768 34 40355
2022-02-09 SC 13G/A filing.txt 0000315066-22-000842 005-91369 22604158 34 7633
2022-02-04 SC 13G us07373v1052_020422.txt 0000834237-22-007299 005-91369 22593565 34 13364
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004198 5435
2022-02-02 4/A FORM 4/A SUBMISSION 0000899243-22-004197 36290
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004196 5726
2022-01-24 3 PRIMARY DOCUMENT 0000315066-22-000058 8609
2022-01-24 SC 13G/A filing.txt 0000315066-22-000057 005-91369 22547619 34 8199
2022-01-10 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-22-000163 001-39208 22519603 34 2466974 1 1
2021-12-30 4 FORM 4 SUBMISSION 0000899243-21-050117 7102
2021-12-23 4 FORM 4 SUBMISSION 0000899243-21-049634 12815
2021-12-22 4 FORM 4 SUBMISSION 0000899243-21-049422 16830
2021-11-08 4 FORM 4 SUBMISSION 0000899243-21-043520 5401
2021-11-08 3 FORM 3 SUBMISSION 0000899243-21-043518 6831
2021-11-08 10-Q 10-Q 0000950170-21-003317 001-39208 211386638 34 12628473 1 1
2021-11-08 8-K 8-K 2.02,5.02,9.01 0000950170-21-003291 001-39208 211386418 34 414443 1 1
2021-10-08 4 FORM 4 SUBMISSION 0000899243-21-039697 22548
2021-09-21 4 FORM 4 SUBMISSION 0000899243-21-036829 7086
2021-09-21 4/A FORM 4/A SUBMISSION 0000899243-21-036823 9936
2021-09-21 4/A FORM 4/A SUBMISSION 0000899243-21-036822 9911
2021-08-26 4 PRIMARY DOCUMENT 0000315066-21-001703 16832
2021-08-20 4 FORM 4 SUBMISSION 0000899243-21-033848 18854
2021-08-16 4/A PRIMARY DOCUMENT 0000315066-21-001702 19943
2021-08-10 4 PRIMARY DOCUMENT 0000315066-21-001699 15116
2021-08-10 10-Q 10-Q 0000950170-21-001110 001-39208 211158448 34 11833672 1 1
2021-08-10 8-K 8-K 2.02,9.01 0000950170-21-001108 001-39208 211158373 34 385195 1 1
2021-07-08 4 FORM 4 SUBMISSION 0000899243-21-027902 28096
2021-07-08 4 FORM 4 SUBMISSION 0000899243-21-027903 31391
2021-07-07 424B5 424B5 0001193125-21-209882 333-254946 211077539 33 369188
2021-07-07 8-K 8-K 1.01,8.01,9.01 0001193125-21-209865 001-39208 211077443 34 208646 1 1
2021-07-02 4 FORM 4 SUBMISSION 0000899243-21-027313 10426
2021-07-02 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-006294 9128
2021-07-02 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-006293 24247
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026782 16369
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026780 22124
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026781 8553
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026779 20268
2021-06-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-006092 31750
2021-06-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-006091 13690
2021-06-23 4 FORM 4 SUBMISSION 0000899243-21-025510 001-40489 211038991 34 7216
2021-06-16 3 FORM 3 SUBMISSION 0000899243-21-024327 001-40489 211023155 34 5080
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023471 5337
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023469 5356
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023467 5323
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023465 5342
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023464 5348
2021-06-11 8-K 8-K 5.07 0001564590-21-032654 001-39208 211011376 34 193844 1 1
2021-06-10 SC 13G SC 13G 0001104659-21-079264 005-91369 211007580 34 45521
2021-06-10 S-3ASR S-3ASR 0001193125-21-187286 333-256962 211006875 33 410378
2021-05-24 8-K 8-K 5.02 0001564590-21-029509 001-39208 21955008 34 162388 1 1

Latest XBRL company facts

One latest value per concept from companyfacts (272 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 103.50M 2026-10-27 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
dei EntityPublicFloat Entity Public Float USD 1.70B 2025-06-30 2025 FY 10-K 2026-02-24 0001193125-26-065194
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 2.58M 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.31M 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 124.75 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 8.40M 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
ecd PeoTotalCompAmt PeoTotalCompAmt USD 5.82M 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 33.95 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161512
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 20.14M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 40.10M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 4.46M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 110.17M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -3.43M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 2.95B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD 1.28M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions APIC, Share-based Payment Arrangement, Recognition and Exercise USD 4.65M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 18.55M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 56.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 206,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 16.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap Assets Assets USD 1.27B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AssetsCurrent Assets, Current USD 1.07B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 26,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 7,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 321.36M 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 321.38M 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 321.38M 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability USD 2.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap BusinessCombinationContingentConsiderationLiabilityCurrent Business Combination, Contingent Consideration, Liability, Current USD 1.49M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap BusinessCombinationContingentConsiderationLiabilityNoncurrent Business Combination, Contingent Consideration, Liability, Noncurrent USD 5.73M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 1.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CashAcquiredFromAcquisition Cash Acquired from Acquisition USD 620,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-27 0000950170-24-020622
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 213.27M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 1.00B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 219.97M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -81.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 250.00M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 103.44M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 103.44M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap CommonStockValue Common Stock, Value, Issued USD 1.03M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -355.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 6.66M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 135.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ContributionOfProperty Contribution of Property USD 25.50M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 303.33M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 29.13M 2019-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 100.00M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD 3.64M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 1.82M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsDerivativeInstruments Deferred Tax Assets, Derivative Instruments USD 2.10M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 484.33M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 141.13M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 58,000 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 100.62M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 26.26M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 7.85M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 455.33M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 27.51M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 1.50M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 267,000 2024-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 2.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.06 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap Depreciation Depreciation USD 16.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 16.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 16.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD 3.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DerivativeLiabilitiesCurrent Derivative Liability, Current USD 4.70M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap DirectFinancingLeaseResidualValueOfLeasedAsset Direct Financing Lease, Residual Value of Leased Asset USD 675,000 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -3.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -3.35 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -3.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.147 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.016 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure -0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.131 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.07 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.127 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.047 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 18.87M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 79.40M 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap EquityMethodInvestmentRealizedGainLossOnDisposal Equity Method Investment, Realized Gain (Loss) on Disposal USD 455,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap EquityMethodInvestments Equity Method Investments USD 0 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap EquitySecuritiesFvNi Equity Securities, FV-NI USD 3.60M 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap EquitySecuritiesFvNiGainLoss Equity Securities, FV-NI, Gain (Loss) USD -667,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 3.01M 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 1.08M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-060683
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 304,000 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-060683
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 2.52M 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Finance Lease, Liability, to be Paid, Year One USD 2.01M 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Finance Lease, Liability, to be Paid, Year Two USD 511,000 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Finance Lease, Liability, Undiscounted Excess Amount USD 192,000 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -43,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 97.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap GuaranteeObligationsCurrentCarryingValue Guarantor Obligations, Current Carrying Value USD 0 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap HeldToMaturitySecurities Debt Securities, Held-to-maturity USD 406.26M 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain USD 14,000 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss USD 38,000 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value USD 82.80M 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value USD 0 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap HeldToMaturitySecuritiesCurrent Debt Securities, Held-to-maturity, Current USD 406.24M 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap HeldToMaturitySecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions Held-to-maturity, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Security 21 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment USD 0 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -79.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -376.70M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap IncomeLossFromEquityMethodInvestments Income (Loss) from Equity Method Investments USD 255.15M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 159,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 11.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -16.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 20,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount USD 3.05M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 10.45M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 10.17M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 5.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -15.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -6.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -10.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 197,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-27 0000950170-24-020622
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 197,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 263,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap InterestAndOtherIncome Interest and Other Income USD 23.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap InterestIncomeOther Interest Income, Other USD 1.36M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-12 0001564590-20-039490
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 5.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Investment Income, Net, Amortization of Discount and Premium USD 8.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LeaseCost Lease, Cost USD 32.51M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 210.14M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 91.16M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 24.73M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 21.01M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 22.15M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 25.66M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 25.44M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 4.69M 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022322
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 56.02M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap Liabilities Liabilities USD 316.40M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.27B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LiabilitiesCurrent Liabilities, Current USD 82.08M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LiabilityForUncertainTaxPositionsCurrent Liability for Uncertainty in Income Taxes, Current USD 0 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap LongTermDebt Long-term Debt USD 100.36M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 100.36M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap LongTermInvestments Long-term Investments USD 24.54M 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap LossContingencyAccrualAtCarryingValue Loss Contingency Accrual USD 20.20M 2024-06-30 2024 Q2 10-Q 2024-08-06 0000950170-24-091242
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 830.61M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap MarketableSecuritiesRealizedGainLoss Marketable Securities, Realized Gain (Loss) USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-053939
us-gaap MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 106.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 117.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -305.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -351.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -351.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 Noncash or Part Noncash Acquisition, Value of Liabilities Assumed USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 23.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingExpenses Operating Expenses USD 407.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -375.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingLeaseCost Operating Lease, Cost USD 21.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 154.12M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 15.64M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 127.86M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingLeasePayments Operating Lease, Payments USD 24.43M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 92.99M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 9.67M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.073 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 5.06M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 7.96M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD -4.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -1.25M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 368,000 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -3,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD -1.19M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap PaymentsForRestructuring Payments for Restructuring USD 4.50M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 813,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 631,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 444.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PaymentsToAcquireEquitySecuritiesFvNi PaymentsToAcquireEquitySecuritiesFvNi USD 750,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap PaymentsToAcquireHeldToMaturitySecurities Payments to Acquire Held-to-maturity Securities USD 289.22M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap PaymentsToAcquireLongtermInvestments Payments to Acquire Long-term Investments USD 750,000 2020-01-01 2020-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003317
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 5.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 25.00M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 23.50M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 93.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 192.51M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 236.57M 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 37.90M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002166
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 566.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities Proceeds from Sale and Maturity of Held-to-maturity Securities USD 20.45M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromSaleOfEquityMethodInvestments Proceeds from Sale of Equity Method Investments USD 455,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 10.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 2.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -351.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 204.21M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 94.04M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap RedeemableNoncontrollingInterestEquityPreferredCarryingAmount Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount USD 302.05M 2019-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party USD 5.50M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 309.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 154.95M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 6.71M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap RestructuringAndRelatedCostIncurredCost Restructuring and Related Cost, Incurred Cost USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated Positions 100 2023-10-01 2023-10-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.2 2023-10-01 2023-10-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap RestructuringCharges Restructuring Charges USD 6.49M 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap RestructuringReserve Restructuring Reserve USD 4.50M 2023-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026076
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.99B 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 32.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap Revenues Revenues USD 6,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 1.52M 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-053939
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 126.60M 2020-10-01 2020-10-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 5.75M 2020-10-01 2020-10-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 23.5 2020-10-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD 28.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 56.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.809 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.797 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 42.18M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 8.21M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 39.19 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 3.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 583,603 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 20.2 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 53.84M 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 12.73M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 34.92 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 15.31 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 42.69 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 28.33 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 4.89M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 952.67M 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 4.484 2020-01-01 2020-01-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap StockIssued1 Stock Issued USD 5.75M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 686,283 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 6.71M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 303.33M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 1.37M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 34.94M 2023-07-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-060683
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 959,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap SubleaseIncome Sublease Income USD 487,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 1.28M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-004866
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 302.05M 2019-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 282.02M 2019-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 130.67M 2019-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2020-12-31 2020 FY 10-K 2021-03-15 0001564590-21-013190
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 17.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap VariableLeaseCost Variable Lease, Cost USD 6.79M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-24 0001193125-26-065194
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 104.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 60.21M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-11 0001564590-21-026555
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 104.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-03 0001193125-26-444455

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →